NASDAQ:FRLN

Freeline Therapeutics (FRLN) Stock Forecast, Price & News

$4.33

+0.42 (+10.74%)

(As of 09/27/2023 ET)

Compare

Today's Range: $3.78
▼
$4.44
50-Day Range: $3.16
▼
$5.10
52-Week Range: $2.11
▼
$12.00

Volume: 53,212 shs
Average Volume: 167,587 shs
Market Capitalization: $18.79 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $13.25

Freeline Therapeutics MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 210.3% Upside
$13.25 Price Target
Short Interest: Healthy
2.50% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($1.04) to ($1.20) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.09 out of 5 stars

Medical Sector

673rd out of 963 stocks

Biological Products, Except Diagnostic Industry

106th out of 159 stocks

3.3

Analyst's Opinion

Consensus Rating
Freeline Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $13.25, Freeline Therapeutics has a forecasted upside of 210.3% from its current price of $4.27.
Amount of Analyst Coverage
Freeline Therapeutics has only been the subject of 2 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
2.50% of the float of Freeline Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Freeline Therapeutics has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Freeline Therapeutics has recently decreased by 2.46%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Freeline Therapeutics does not currently pay a dividend.
Dividend Growth
Freeline Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for FRLN.

2.7

News and Social Media Coverage

News Sentiment
Freeline Therapeutics has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.86 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Freeline Therapeutics this week, compared to 1 article on an average week.
Search Interest
Only 1 people have searched for FRLN on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Freeline Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Freeline Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 1.90% of the stock of Freeline Therapeutics is held by insiders.
Percentage Held by Institutions
46.26% of the stock of Freeline Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Freeline Therapeutics are expected to decrease in the coming year, from ($1.04) to ($1.20) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Freeline Therapeutics is -0.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Freeline Therapeutics is -0.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Freeline Therapeutics has a P/B Ratio of 0.35. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Freeline Therapeutics (NASDAQ:FRLN) Stock

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies. It develops FLT180a for the treatment of hemophilia B.; FLT201 for the treatment of Type 1 Gaucher disease; and FLT190 for the treatment of Fabry disease. in addition, it has research programs for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.

FRLN Price History

30 days | 90 days | 365 days | Advanced Chart

FRLN Stock News Headlines

August 17, 2023 | markets.businessinsider.com

H.C. Wainwright Sticks to Their Buy Rating for Freeline Therapeutics Holdings (FRLN)

August 17, 2023 | finance.yahoo.com

Freeline Therapeutics Holdings plc (NASDAQ:FRLN) Q2 2023 Earnings Call Transcript

September 27, 2023 | Tradewins (Ad)

The Safest Option in Trades!

If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult. And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!

August 16, 2023 | markets.businessinsider.com

4 Analysts Have This to Say About Freeline Therapeutics

August 16, 2023 | finance.yahoo.com

Q2 2023 Freeline Therapeutics Holdings PLC Earnings Call

August 15, 2023 | seekingalpha.com

Freeline Therapeutics GAAP EPS of -$0.23 beats by $3.28, revenue of $0.62M

August 15, 2023 | finanznachrichten.de

Freeline Therapeutics Holdings plc: Freeline Reports Second Quarter 2023 Financial Results and Business Highlights

August 15, 2023 | finance.yahoo.com

Freeline Reports Second Quarter 2023 Financial Results and Business Highlights

September 27, 2023 | Chaikin Analytics (Ad)

This Stock Could Go Up 66% or More.

Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023. Click here to get his latest buy. More here.

August 14, 2023 | benzinga.com

Freeline Therapeutics's Earnings: A Preview

August 8, 2023 | finance.yahoo.com

Freeline Therapeutics to Host Second Quarter 2023 Financial Results Call

July 25, 2023 | finance.yahoo.com

Freeline to Host Virtual KOL Event on its Gene Therapy Candidate, FLT201, in Gaucher Disease

July 20, 2023 | thestreet.com

Freeline Therapeutics Holdings plc

July 13, 2023 | benzinga.com

Freeline Therapeutics Holdings Shares Halted On Circuit Breaker To The Upside, Up 53.1%

July 13, 2023 | finance.yahoo.com

Estimating The Fair Value Of Freeline Therapeutics Holdings plc (NASDAQ:FRLN)

June 26, 2023 | tmcnet.com

Freeline Announces First Patient Dosed with Its Novel

June 26, 2023 | finance.yahoo.com

Freeline Announces First Patient Dosed with Its Novel Gene Therapy Candidate for Gaucher Disease and Unveils Research Program in GBA1-linked Parkinson’s Disease

June 13, 2023 | finance.yahoo.com

Freeline Therapeutics Holdings PLC Sponsored ADR (FRLN) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

June 7, 2023 | markets.businessinsider.com

Stifel Nicolaus Keeps Their Hold Rating on Freeline Therapeutics Holdings (FRLN)

June 2, 2023 | finance.yahoo.com

Freeline to Present at 2023 Jefferies Healthcare Conference

May 30, 2023 | finanznachrichten.de

Freeline Therapeutics Holdings plc: Freeline Reports First Quarter 2023 Financial Results and Business Highlights

May 30, 2023 | finance.yahoo.com

Freeline Reports First Quarter 2023 Financial Results and Business Highlights

May 22, 2023 | finance.yahoo.com

Freeline Granted ILAP Designation in United Kingdom by MHRA for FLT201, an Investigational Gene Therapy for the Treatment of Gaucher Disease

May 14, 2023 | investing.com

Freeline (FRLN) Earnings Dates & Reports

May 12, 2023 | finanznachrichten.de

Freeline Therapeutics Holdings plc: Freeline Completes ADS Ratio Change

May 12, 2023 | finance.yahoo.com

Both private equity firms who control a good portion of Freeline Therapeutics Holdings plc (NASDAQ:FRLN) along with institutions must be dismayed after last week's 11% decrease

May 12, 2023 | finance.yahoo.com

Freeline Completes ADS Ratio Change

See More Headlines

Receive FRLN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Freeline Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

FRLN Company Calendar

Last Earnings: 8/15/2023
Today: 9/27/2023
Next Earnings (Estimated): 11/21/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:FRLN
CUSIP: N/A
CIK: 1810031
Web: www.freeline.life
Phone: 44-0-14-3890-6870
Fax: N/A
Employees: 152
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $13.25
High Stock Price Forecast: $30.00
Low Stock Price Forecast: $3.00
Forecasted Upside/Downside: +211.0%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($8.3990)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-88,970,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -129.10%
Return on Assets: -85.49%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.45
Quick Ratio: 2.81

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $12.07 per share
Price / Book: 0.35

Miscellaneous

Outstanding Shares: 4,340,000
Free Float: 4,259,000
Market Cap: $18.49 million
Optionable: Not Optionable
Beta: 0.68

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

Mr. Michael J. Parini J.D. (Age 48)
CEO & Exec. Director
Comp: $2.16M

Mr. Paul M. Schneider (Age 52)
CFO & Director

Dr. Henning R. Stennicke Ph.D. (Age 55)
Chief Scientific Officer

Ms. Nicole Jones SPHR (Age 52)
Chief People Officer

Mr. James Bircher (Age 55)
Chief Technical Operations Officer

Dr. Pamela Foulds M.D. (Age 53)
Chief Medical Officer

Ms. Naomi Aoki
Sr. VP of Corp. Communications & Investor Relations

Ms. Amy J. Spandau (Age 48)
Interim Head of Fin.

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

FRLN Stock - Frequently Asked Questions

Should I buy or sell Freeline Therapeutics stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Freeline Therapeutics in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" FRLN shares.
View FRLN analyst ratings or view top-rated stocks.
What is Freeline Therapeutics' stock price forecast for 2023?: 3 equities research analysts have issued twelve-month price objectives for Freeline Therapeutics' stock. Their FRLN share price forecasts range from $3.00 to $30.00. On average, they anticipate the company's stock price to reach $13.25 in the next year. This suggests a possible upside of 211.0% from the stock's current price.
View analysts price targets for FRLN or view top-rated stocks among Wall Street analysts.
How have FRLN shares performed in 2023?: Freeline Therapeutics' stock was trading at $7.1265 on January 1st, 2023. Since then, FRLN stock has decreased by 40.2% and is now trading at $4.26.
View the best growth stocks for 2023 here.
When is Freeline Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 21st 2023.
View our FRLN earnings forecast.
How were Freeline Therapeutics' earnings last quarter?: Freeline Therapeutics Holdings plc (NASDAQ:FRLN) announced its quarterly earnings data on Tuesday, August, 15th. The company reported ($0.21) EPS for the quarter, beating analysts' consensus estimates of ($3.62) by $3.41. The business earned $0.62 million during the quarter.
When did Freeline Therapeutics' stock split?: Freeline Therapeutics shares reverse split on Friday, May 12th 2023. The 1-15 reverse split was announced on Friday, May 12th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.
What other stocks do shareholders of Freeline Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Freeline Therapeutics investors own include Adobe (ADBE), BigCommerce (BIGC), Checkmate Pharmaceuticals (CMPI), CVS Health (CVS), Old Dominion Freight Line (ODFL), Oak Street Health (OSH), Rocket Companies (RKT), Shopify (SHOP), Zoom Video Communications (ZM) and Zymeworks (ZYME).

When did Freeline Therapeutics IPO?: (FRLN) raised $126 million in an initial public offering (IPO) on Friday, August 7th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Morgan Stanley and Evercore ISI acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.
What is Freeline Therapeutics' stock symbol?: Freeline Therapeutics trades on the NASDAQ under the ticker symbol "FRLN."
Who are Freeline Therapeutics' major shareholders?: Freeline Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Syncona Portfolio Ltd (33.79%), Renaissance Technologies LLC (0.50%), CHI Advisors LLC (0.50%), Northern Trust Corp (0.36%) and Harbor Capital Advisors Inc. (0.25%).
How do I buy shares of Freeline Therapeutics?: Shares of FRLN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Freeline Therapeutics' stock price today?: One share of FRLN stock can currently be purchased for approximately $4.26.
How much money does Freeline Therapeutics make?: Freeline Therapeutics (NASDAQ:FRLN) has a market capitalization of $18.49 million. The company earns $-88,970,000.00 in net income (profit) each year or ($8.3990) on an earnings per share basis.
How many employees does Freeline Therapeutics have?: The company employs 152 workers across the globe.
How can I contact Freeline Therapeutics?: Freeline Therapeutics' mailing address is STEVENAGE BIOSCIENCE CATALYST GUNNELS WOOD ROAD STEVENAGE, HERTFORDSHIRE X0, SG12FX. The official website for the company is www.freeline.life. The company can be reached via phone at 44-0-14-3890-6870 or via email at ir@freeline.life.

This page (NASDAQ:FRLN) was last updated on 9/27/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial